- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA approves Imagent
Alliance Pharmaceutical will kick off its marketing campaign for ultrasound contrast agent Imagent June 9 at the annual meeting of the American Society of Echocardiography in Orlando. The commercial release follows recent FDA approval of the agent to
Alliance Pharmaceutical will kick off its marketing campaign for ultrasound contrast agent Imagent June 9 at the annual meeting of the American Society of Echocardiography in Orlando. The commercial release follows recent FDA approval of the agent to opacify the left ventricle in patients with suboptimal echocardiograms. Imagent, formerly known as Imavist, will be marketed by Alliance in partnership with Cardinal Health and inChord Communications. Imagent is manufactured from synthetic materials and packaged as a dry powder in a ready-to-use kit stored at room temperature. The powder is reconstituted with water to form an osmotically stabilized suspension of microscopic spheres, or microspheres, containing a perfluorochemical (perflexane) vapor and physiologic gases. Imagent is then injected intravenously into a patient undergoing a cardiac ultrasound exam.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
